The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety (INTERFAT)

March 7, 2017 updated by: Dr Sarah Berry, King's College London

The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety: a Randomised Controlled Trial. The INTER-FAT Study

The purpose of this study is to investigate whether there are differences in postprandial metabolic indices following interesterified fats used in commercial spreads versus the corresponding un-interesterified blend.

Study Overview

Detailed Description

Aim: The current study aims to investigate the acute effects of commercially relevant interesterified 'hardstock' versus the corresponding un-interesterified blend on postprandial lipaemia, glycaemia, insulinaemia and gut hormone responses. Due to the previously observed differences in gut hormones following interesterified palm oil and un-interesterified palm oil by our group, we will also explore acute effects of these fats on satiety and rates of gastric emptying.

Hypothesis: Interesterification of a palm kernel and palm stearin fat blend, to produce a fat with a higher proportion of palmitic acid in the middle position of the TAG (but the same fatty acid composition), will alter postprandial lipid and glucose metabolism. It is also hypothesised that differences in rates of absorption between the test fats will influence gut hormone responses and feelings of satiety.

Subjects: Participants will include 10 healthy male volunteers. In order to determine the 'typical' response to the test fats, subjects must not be affected by metabolic syndrome in any way (obesity, dyslipidemia, insulin resistance or hypertension), they must be non-smokers (since smoking influences postprandial lipaemia), and be aged between the ages of 18 and 45 years (since above this age metabolic changes may take place that may affect the way that the body digests and metabolises lipids). Male volunteers have been selected as they elicit a higher postprandial lipaemic response to a given fat load and therefore are more sensitive to dietary manipulation.

Power calculation: A sample size of 10 has 80% power to detect a difference between means of 112.74 units in area under the curve in plasma TAG with a significance level (alpha) of 0.05 (two-tailed).

Expected value:

The study will provide novel information on the acute effects of commercially relevant spreads on postprandial lipaemia and satiety. It will also explore possible mechanisms for the predicted reduced lipaemia following the interesterified fat from measurements of gastric emptying.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • London, United Kingdom, SE1 9NH
        • Diabetes and Nutritional Sciences Division, School of Medicine, Kings College London

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. Age: 18-45
  2. Male
  3. Healthy (free of diagnosed diseases listed in exclusion criteria)
  4. Able to understand the information sheet and willing to comply with study protocol
  5. Able to give informed consent

Exclusion criteria:

  1. Medical history of myocardial infarction, angina, thrombosis, stroke, cancer, liver or bowel disease or diabetes
  2. Body mass index < 20 kg/m2 or > 35 kg/m2
  3. Plasma cholesterol ≥7.5 mmol/L
  4. Plasma triacylglycerol > 3 mmol/L
  5. Plasma glucose > 7 mmol/L
  6. Blood pressure ≥160/100 mmHg
  7. Current use of antihypertensive or lipid lowering medications
  8. Alcohol intake exceeding a moderate intake (> 28 units per week)
  9. Current cigarette smoker
  10. ≥ 20% 10-year risk of cardiovascular disease as calculated using risk calculator
  11. Ingestion of paracetamol in the preceding 24 hrs to study days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Interesterified
Interesterified blend of palm kernal and plam stearin. 50g fat.
50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
Other Names:
  • Interesterified blend
Active Comparator: Un-interesterified
Un-interesterified blend of palm kernal and plam stearin. 50g fat.
50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
Other Names:
  • Un-interesterified blend

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postprandial lipaemia (Postprandial plasma triacylglycerol concentrations)
Time Frame: Postprandial 4 hrs
Postprandial plasma triacylglycerol concentrations
Postprandial 4 hrs

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycemia (Postprandial plasma glucose and insulin concentrations)
Time Frame: Postprandial 4 hrs
Postprandial plasma glucose and insulin concentrations
Postprandial 4 hrs
Gut hormones (Postprandial gut peptide YY and glucose-dependent insulinotropic polypeptide concentrations)
Time Frame: Postprandial 4 hrs
Postprandial gut peptide YY and glucose-dependent insulinotropic polypeptide concentrations
Postprandial 4 hrs

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Satiety (Postprandial visual analogue scales)
Time Frame: Postprandial 4 hrs
Postprandial visual analogue scales
Postprandial 4 hrs
Gastric emptying (Postprandial paracetamol concentrations)
Time Frame: Postprandial 4 hrs
Postprandial paracetamol concentrations
Postprandial 4 hrs

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sarah EE Berry, BSc,MSc,PhD, King's College London

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (Actual)

June 1, 2015

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

February 11, 2015

First Submitted That Met QC Criteria

February 18, 2015

First Posted (Estimate)

February 19, 2015

Study Record Updates

Last Update Posted (Actual)

March 9, 2017

Last Update Submitted That Met QC Criteria

March 7, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • BDM/14/15-26

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Men

Clinical Trials on Interesterified blend of palm kernal and plam stearin

Subscribe